COST-EFFECTIVENESS ANALYSIS OF PATIROMER IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION FOR THE TREATMENT OF HYPERKALEMIA: ANALYSIS OF THE DIAMOND CLINICAL TRIAL

被引：0
|
作者：
Stawowczyk, E. [1 ]
Turner, M. [1 ]
Lewis, R. D. [1 ]
Lloyd, I. T. [1 ]
Ruiz, O. [2 ]
Serna, Ramirez De Arellano A. [3 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[2] CSL Vifor, Barcelona, Spain
[3] CSL Vifor, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE457
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
    Sang, Haiqiang
    Wan, Yiming
    Ma, Zhenzhou
    Zhang, Shengye
    Zhao, Qiuping
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [22] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    CIRCULATION, 2020, 142
  • [23] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [24] A COST-EFFECTIVENESS ANALYSIS OF RAASI - ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN AUSTRIA
    Walter, E.
    Eichhober, G.
    Voit, M.
    VALUE IN HEALTH, 2018, 21 : S456 - S456
  • [25] A COST-EFFECTIVENESS ANALYSIS OF RAASI - ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN
    Widen, J.
    Nousios, P.
    Ivarsson, M.
    Schalin, L.
    Sutherland, C. S.
    Ademi, Z.
    Schwenkglenks, M.
    Vrouchou, P.
    VALUE IN HEALTH, 2018, 21 : S477 - S477
  • [26] Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
    Lin, Xiaohui
    Lin, Minhua
    Liu, Maobai
    Huang, Weiying
    Nie, Xuekun
    Chen, Zichun
    Zheng, Bin
    JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1588 - 1597
  • [27] COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN SPAIN
    Lacasa, C.
    Obradors, M.
    Figueras, M.
    Perez-Alcantara, F.
    Brosa, M.
    VALUE IN HEALTH, 2016, 19 (07) : A650 - A650
  • [28] Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
    Tsutsui, Hiroyuki
    Sakamaki, Hiroyuki
    Momomura, Shin-ichi
    Sakata, Yasushi
    Kotobuki, Yutaro
    Linden, Stephan
    Idehara, Koki
    Nitta, Daisuke
    ESC HEART FAILURE, 2024, 11 (01): : 261 - 270
  • [29] COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTION IN SPAIN
    Fernandez de Bobadilla, J.
    Gonzalez Fernandez, O.
    Lopez de Sa, E.
    Lopez-Sendon, J. L.
    VALUE IN HEALTH, 2014, 17 (07) : A486 - A486
  • [30] COST-EFFECTIVENESS ANALYSIS OF ARNI COMPARED TO ACEI AMONG HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION IN MALAYSIA
    Kuan, Wc
    Ademi, Z.
    Lee, Sw
    Ong, Sc
    Chee, Kh
    Kasim, S.
    Shariff, R. E. Raja
    Ghazi, A. Mohd
    Kader, M. A. S. K. Abdul
    Lim, Kk
    Shetty, S.
    Fox-Rushby, J.
    Dujaili, J.
    Lee, Kkc
    Teoh, Sl
    VALUE IN HEALTH, 2024, 27 (12)
12345